investors

Press Releases

DateTitle and SummaryView
October 17, 2018
LOS ANGELES , Oct. 17, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that on October 16, 2018 , the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings
ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards
October 15, 2018
Management Team to Transition to Consulting Roles in Effort to Streamline Operations and Manage Expenses LOS ANGELES , Oct. 15, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw
ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants
August 13, 2018

-Ongoing Exploration of Strategic Opportunities- -Continued Progress in Stem-to-T-Cell Program- LOS ANGELES , Aug. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
July 19, 2018

Settlement Will Be Paid By Company's Insurance Carrier LOS ANGELES , July 19, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell

ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit
May 14, 2018
-Continued Progress in Stem-to-T-Cell Program-
-Ongoing Exploration of Strategic Opportunities-
ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results
April 12, 2018
LOS ANGELES , April 12, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular " or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells.
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
March 26, 2018
LOS ANGELES , March 26, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular ") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March
ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation
March 13, 2018
-Continued Progress in Stem-to-T-Cell Program-
-Strengthened Financial Condition-
-Conference Call Today at 5:00 pm ET-
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
March 7, 2018
LOS ANGELES , March 7, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE American: IMUC) today announced that it plans to report fourth quarter and full year 2017 financial results on Tuesday, March 13, 2018 . The Company also plans to hold a conference call and
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
February 22, 2018
LOS ANGELES , Feb. 22, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has retained Ladenburg
ImmunoCellular Therapeutics Announces Review of Strategic Alternatives
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved